Efficacy of bacopa monnieri (Brahmi) and Donepezil in Alzheimer's Disease and mild cognitive impairment: A randomized double-blind parallel Phase 2b study

Efficacy of bacopa monnieri (Brahmi) and Donepezil in Alzheimer's Disease and mild cognitive impairment: A randomized double-blind parallel Phase 2b study

Objectives: Alzheimer's disease (AD) is the most common cause of dementia worldwide in the older population. There is no disease-modifying therapy available for AD. The current standard of care drug therapy for AD is cholinesterase inhibitors, including donepezil. Bacopa monnieri or brahmi is u...

Full description

Bibliographic Details
Main Authors: Sudesh Prabhakar, Venugopalan Y Vishnu, Manish Modi, Manju Mohanty, Anchal Sharma, Bikas Medhi, B R Mittal, Niranjan Khandelwal, Manoj K Goyal, Vivek Lal, Rajesh Singla, Avinash Kansal, Ajit Avasthi
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Annals of Indian Academy of Neurology
Subjects:
alzheimer's disease
bacopa monnieri
brahmi
donepezil
dementia
mild cognitive impairment
Online Access:http://www.annalsofian.org/article.asp?issn=0972-2327;year=2020;volume=23;issue=6;spage=767;epage=773;aulast=Prabhakar

Internet

http://www.annalsofian.org/article.asp?issn=0972-2327;year=2020;volume=23;issue=6;spage=767;epage=773;aulast=Prabhakar

Similar Items